about
Genetic architecture of HIV-1 genes circulating in north India & their functional implicationsLong-term efficacy of first line antiretroviral therapy in Indian HIV-1 infected patients: a longitudinal cohort studySubtype-independent near full-length HIV-1 genome sequencing and assembly to be used in large molecular epidemiological studies and clinical managementThe expanding HIV-1 epidemic aggravates therapeutics and vaccine development programs in IndiaQuantitative humoral profiling of the HIV-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy.Phylogenetic characterization of six full-length HIV-1 subtype C molecular clones from three patients: identification of rare subtype C strains containing two NF-κB motifs in the long terminal repeatTemporal trends in the Swedish HIV-1 epidemic: increase in non-B subtypes and recombinant forms over three decades.Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in SwedenCo-receptor tropism prediction among 1045 Indian HIV-1 subtype C sequences: Therapeutic implications for India.Genetic and functional analysis of HIV-1 Rev Responsive Element (RRE) sequences from North-India.The gp120 protein is a second determinant of decreased neurovirulence of Indian HIV-1C isolates compared to southern African HIV-1C isolates.Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.Molecular epidemiology of HIV-1 subtypes in India: origin and evolutionary history of the predominant subtype C.Novel tetra-peptide insertion in Gag-p6 ALIX-binding motif in HIV-1 subtype C associated with protease inhibitor failure in Indian patients.High viremia and low level of transmitted drug resistance in anti-retroviral therapy-naïve perinatally-infected children and adolescents with HIV-1 subtype C infectionGut microbiota diversity predicts immune status in HIV-1 infection.Genetic characterization of HIV type 1 Tat exon 1 from a southern Indian clinical cohort: identification of unique epidemiological signature residues.Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries.Multiple NF-κB sites in HIV-1 subtype C long terminal repeat confer superior magnitude of transcription and thereby the enhanced viral predominance.Can HIV reverse transcriptase activity assay be a low-cost alternative for viral load monitoring in resource-limited settings?Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals.Dried blood spot HIV-1 RNA quantification: a useful tool for viral load monitoring among HIV-infected individuals in IndiaSelection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance.Clade C HIV-1 isolates circulating in Southern Africa exhibit a greater frequency of dicysteine motif-containing Tat variants than those in Southeast Asia and cause increased neurovirulence.Genetic analysis of HIV-1 Circulating Recombinant Form 02_AG, B and C subtype-specific envelope sequences from Northern India and their predicted co-receptor usage.Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients.Phylogenetic Analysis of Ethiopian HIV-1 Subtype C Near Full-Length Genomes Reveals High Intrasubtype Diversity and a Strong Geographical Cluster.Performance of genotypic tools for prediction of tropism in HIV-1 subtype C V3 loop sequences.HIV-1 coreceptor tropism in India: increasing proportion of X4-tropism in subtype C strains over two decades.Cost-efficient HIV-1 drug resistance surveillance using multiplexed high-throughput amplicon sequencing: implications for use in low- and middle-income countries.Higher prevalence of predicted X4-tropic strains in perinatally infected older children with HIV-1 subtype C in India.Genetic architecture of HIV type 1 Nef and Tat from HLA-B57-typed long-term survivors in an Indian cohort of perinatally HIV-infected children.Effectiveness of first-line antiretroviral therapy and acquired drug resistance among HIV-1-infected children in India.Recent increased identification and transmission of HIV-1 unique recombinant forms in Sweden.A high rate of HIV-1 acquisition post immigration among migrants in Sweden determined by a CD4 T-cell decline trajectory model.Increased replication capacity following evolution of PYxE insertion in Gag-p6 is associated with enhanced virulence in HIV-1 subtype C from East Africa.Multiplexed next-generation sequencing and de novo assembly to obtain near full-length HIV-1 genome from plasma virus.Mutational Heterogeneity in p6 Gag Late Assembly (L) Domains in HIV-1 Subtype C Viruses from South Africa.Virological efficacy with first-line antiretroviral treatment in India: predictors of viral failure and evidence of viral resuppression.
P50
Q26866018-5E83C629-7BAA-422A-98B3-E2712A796DE4Q28485373-F65B0E5E-1FE6-4574-AF16-3AE5DDA9CA19Q30376101-89682DC1-BBDA-40CF-A1D4-52307F35400AQ30386245-22908EEF-5899-4B82-A22D-C3FB68E27565Q33677727-4ABBDC9B-66E0-4AAF-BAD3-34F19B3E4B92Q33713838-2E5A5032-9C2A-4955-B834-EDAAFBF86B2FQ33748955-8F7EF63B-74D0-4802-B1D4-F1F35FD36629Q33764793-E422683D-57EA-4472-81DA-C62632056E67Q33856712-95CE7361-6EAC-4168-9AD5-44B7747FAB9BQ34053466-24982E75-3FF3-4A7C-8E47-2F8B4C36A488Q34060633-C4F7DD83-5D56-49A2-BD27-C5BFDA681137Q34134168-A34390F9-0FE1-4E0E-A6AB-1ED82CA75B82Q34303603-53444027-785D-4D1B-811B-F4BA2E3F8EECQ34328297-19603275-1702-4F3B-BC28-341FB57F6E9AQ34345067-4513F9AD-EE06-4740-A845-AE641BF0AB6BQ34484449-361106B2-05FA-47E9-84F9-45F0B6DDE925Q35768934-893E530F-AF12-4C17-83D4-248530945688Q36177574-ECF8CBA7-848F-43DC-948A-68A8E35B4459Q36455357-1077BAE6-8ACA-49A6-BC37-840346F50C66Q36492916-A16F07C7-A4BE-4656-9C13-5CB5AD81C04AQ36526686-82CB67D7-FDB9-41A4-8E5F-A58464564C05Q36639618-0A381233-8510-4400-8EBB-C0DB25FA622FQ36728682-4720F0D8-1D62-4B4A-904B-3C129BB73EE4Q36799767-109A306E-1506-47A1-AA78-C32060A5C874Q36940756-7E0E4246-DC1E-40C8-8A13-9B8846C9CA13Q37479741-FBA5A28B-3B7B-48B3-86BB-746229097D40Q38669988-CFA70033-3B8C-4A20-BDF5-05E4B160ED3DQ38873351-394243D1-EF72-4720-8627-353A94D7271CQ39037370-EB656776-E7B9-4197-AFA8-5A17198169C5Q39037382-F6DB50C3-0785-4DB4-B383-496741E95C30Q39149710-8A9A4FE1-F8DC-48A5-8BB6-FB872F6E19FCQ39299363-B1673254-13CD-4125-B1FD-CF9CFCCC29A1Q39352709-00CD7B78-1765-45C9-946D-77CE45CFCB30Q39501442-5DB5A209-03AD-4415-B9C9-985CFAC97CEBQ40108513-6D9A7331-01BB-48CD-AD50-130C187AB9ADQ40236978-49012D42-C90E-42D8-B468-B66EAEAD4FCDQ40473808-5A97CFAD-3F09-4603-B2A1-508ED9A24FBCQ40603029-FD61EA71-99DA-4BDE-AF6F-A8D95B3CB092Q40977735-E0D78CB7-6DB5-4BC5-9B5F-B57F18513126Q41610672-EAD4A0DF-F498-43F1-895D-F72AAFF3650D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ujjwal Neogi
@ast
Ujjwal Neogi
@en
Ujjwal Neogi
@es
Ujjwal Neogi
@nl
Ujjwal Neogi
@sl
type
label
Ujjwal Neogi
@ast
Ujjwal Neogi
@en
Ujjwal Neogi
@es
Ujjwal Neogi
@nl
Ujjwal Neogi
@sl
prefLabel
Ujjwal Neogi
@ast
Ujjwal Neogi
@en
Ujjwal Neogi
@es
Ujjwal Neogi
@nl
Ujjwal Neogi
@sl
P106
P1153
18634521100
P31
P496
0000-0002-0844-3338